RiskReversal Pod cover image

Marketplace Thriller and a Conversation with Cameron Dawson

RiskReversal Pod

00:00

Valuation Challenges in Pharma and Tech

This chapter explores the recent performance and valuation concerns of pharmaceutical companies Eli Lilly and Novo Nordisk, particularly in the wake of disappointing sales for key drugs. It highlights the market reactions, trade dynamics among hedge funds, and the implications of ethical concerns surrounding auditing firms in the tech sector, especially related to SMCI. Additionally, the chapter examines revenue fluctuations and potential vulnerabilities in the business models of major players like NVIDIA, drawing parallels to historical tech trends.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app